Summary
The MICs of rifabutin onMycobacterium avium are compatible with its efficacy in clinical infections. Two North American trials established the prophylactic effect of rifabutin in disseminatedM. avium disease in AIDS patients. Several prospective non-randomized trials show the clinical and bacteriological efficacy of rifabutin. A large European study conducted from 1990 to 1993 randomized 382 patients, selected on a clinical basis, to receive a combination of ethambutol + clofazimine + isoniazid + placebo or rifabutin for 12 weeks. Of these, 200 were eligible, i.e. had a positive blood culture at day 0. The percentage of patients with fever decreased from 78% to 23% in the rifabutin arm and from 76% to 11% in the placebo group (difference statistically not significant). The percentage of positive blood cultures decreased from 100% to 70% and 29% in the placebo group and from 100% to 45% and 18% in the rifabutin group at weeks 0, 6 and 12 respectively. The rate of adverse events was 35% in the placebo and 30% in the rifabutin group (difference statistically not significant). Two other French randomized trials are being analysed: the first one compares a 14-day regimen of rifabutin to placebo. It shows a 70% success rate in the rifabutin arm and a 8% success rate in the control group. The second trial demonstrates that when given in addition to clarithromycin, unlike clofazimine a combination of rifabutin + ethambutol is effective in decreasing the relapse rate with acquired resistance to clarithromycin. After clarithromycin, rifabutin is the second drug which was proven to be active against disseminatedM. avium disease in a controlled placebo trial.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Horsburgh, C. R. Jr. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N. Engl. J. Med. 324 (1991) 1332–1338.
Dautzenberg, B., Chauvin, J. P., Koulaksezian, A., Lecoeur, L. Les infections à mycobactéries non tuberculeuses mises sous traitements expérimentaux en France. Bulletin Epidemiologique Hebdomadaire 44 (1992) 208–209.
Nightingale, S. D., Byrd, L. T., Southern, P. M., Jockusch, J. D., Cal, S. X., Wynne, B. A. Incidence ofMycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J. Infect. Dis. 165 (1992) 1082–1085.
Snider, D. E. Jr., Hopewell, P. C., Mills, J., Reichman, L. B. Mycobacteriosis and the acquired immunodeficiency syndrome. Am. Rev. Respir. Dis. 136 (1987) 492–496.
Chin, D. P., Reingold, A. L., Stone, E. N., Vittinghoff, E., Horsburgh, C. R., Simon, E. M., Yajko, D. M., Madley, W. K., Ostroff, S. M., Mopewell, P. C. The impact ofMycobacterium avium complex bacteremia and its treatment on survival of AIDS patients — A prospective study. J. Infect. Dis. 170 (1994) 578–584.
Dautzenberg, B., Truffot, C., Mignon, A., Rozenbaum, W., Katlama, C., Perronne, C., Parrot, R., Grosset, J., andthe GETIM Rifabutin in combination with clofazimine, isoniazid and ethambutol in the treatment of AIDS patients with infections due to opportunistic mycobacteria. Tubercle 72 (1991) 168–175.
Brogden, R. N., Fitton, A. Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 47 (1994) 983–1009.
Hoy, J., Mijch, A., Sandland, M., Grayson, L., Lucas, R., Dwyer, B. Quadruple-drug therapy forMycobacterium avium-intracellulare bacteremia in AIDS patients. J. Infect. Dis. 161 (1990) 801–805.
Masur, H., Tuazon, C., Gill, V, Grimes, G., Bairs, B., Fauci, A. S., Lane, H. C. Effect of combined clofazimine and ansamycin therapy ofMycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. J. Infect. Dis. 155 (1987) 127–129.
Nightingale, S. D., Cameron, D. W., Gordin, F. M., Sullam, P. M., Cohn, D. L., Chaisson, R. E., Eron, L. J., Sparti, P. D., Binari, B., Kaufman, D. L., Stern, J. J., Pearce, D. D., Weinberg, W. G., LaMarca, A., Siegal, F. P. Two controlled trials of rifabutin prophylaxis againstMycobacterium avium complex infection in AIDS. N. Engl. J. Med. 329 (1993) 828–833.
Centers for Disease Control and Prevention (CDC) Recommendations on prophylaxis and therapy for disseminatedMycobacterium avium complex for adults and adolescents infected with human immunodeficiency virus. MMWR Morb. Mortal. Wkly. Rep. 42 (1993) 14–20.
Dautzenberg, B., Truffot, C., Legris, S., Meyohas, M. C., Legris, S., Mercat, A., Chevret, S., Grosset, J. Activity of clarithromycin againstMycobacterium avium infection in patients with the acquired immune deficiency syndrome. Am. Rev. Respir. Dis. 144 (1991) 564–569.
Chaisson, R. E., Benson, C. A., Dube, M. P., Heifets, L. B., Korvick, J. A., Elkin, S., Smith, J., Craft, J. C., Sattler, F. R., andthe AIDS Clinical Trials Group Protocol 157 Study Team Clarithromycin therapy for bacteremicMycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. Ann. Intern. Med. 121 (1994) 905–911.
Dautzenberg, B., Ruf, B., Esposito, R., Opravil, M., Hoy, J., Olliaro, P. and the Rifabutin Study Group: Rifabutin vs placebo in combination therapy for the treatment of disseminated MAC in HIV+ patients. ICAAC Orlando −4/7 October 1994 Late Breaker A1.
Sullam, P. M., Gordin, F. M., Wynne, B. A. andthe Rifabutin Treatment Group Efficacy of rifabutin in the treatment of disseminated infection due toMycobacterium avium complex. Clin. Infect. Dis. 19 (1994) 84–86.
May, T., Brel, F., Beuscart, C., Vincent, V., Perronne, C., Saint-Marc, T., Dautzenberg, B., Grosset, J. and Curavium Group: A French randomized open trial of 2 clarithromycin combination therapies forM. avium bacteremia: first results. ICAAC 1995; LB18.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dautzenberg, B. The use of rifabutin in Europe for the treatment of mycobacterial infection in AIDS patients. Infection 25, 63–66 (1997). https://doi.org/10.1007/BF02113518
Issue Date:
DOI: https://doi.org/10.1007/BF02113518